Table 1.
Lipid-lowering therapies, overall and by cardiovascular risk level.
| Variable | No. of patients (n = 9049) | Risk level |
||||
|---|---|---|---|---|---|---|
| Low (n = 70) | Moderate (n = 411) | High (n = 2621) | Very high (n = 4842) | Not assesseda (n = 1105) | ||
| LLT | ||||||
| Any statin | 8863 (97.9) | 64 (91.4) | 394 (95.9) | 2550 (97.3) | 4782 (98.8) | 1073 (97.1) |
| High intensity statin (in statin-treated patients)b | 2238/8863 (25.3) | 14/64 (21.9) | 88/394 (22.3) | 415/2550 (16.3) | 1554/4782 (32.5) | 167/1073 (15.6) |
| On highest dose (in statin-treated patients)c | 2072/8852 (23.4) | 13/64 (20.3) | 83/394 (21.1) | 441/2547 (17.3) | 1322/4776 (27.7) | 213/1071 (19.9) |
| Statin monotherapy | 7770 (85.9) | 50 (71.4) | 316 (76.9) | 2232 (85.2) | 4225 (87.3) | 947 (85.7) |
| Statin+fibrate±other LLT | 630 (7.0) | 13 (18.6) | 38 (9.2) | 219 (8.4) | 284 (5.9) | 76 (6.9) |
| Statin+cholesterol absorption inhibitor±other LLT | 272 (3.0) | 0 | 26 (6.3) | 68 (2.6) | 154 (3.2) | 24 (2.2) |
Data are presented as n (%) or n/n (%) values.
LLT: lipid-lowering therapy.
a
Patients without a serious pathology classifying them as very high or high cardiovascular risk, and in whom the SCORE could not be calculated due to missing data.
b
Atorvastatin 40/80 mg or rosuvastatin 20/40 mg.
c
Marketed in the country.